NovelStem Provides Shareholder Update
The original release is unavailable here.
NovelStem International Corp. on 6ix
Earlier from NovelStem International
- Hollywood Media Changes Name and Stock Symbol to NovelStem International Corp. and “NSTM” to Reflect Focus on Stem Cell-Based Diagnostics to Better Select Cancer Chemotherapies
- NewStem Announces $4 million Seed Investment
- Hollywood Media Completes Transformational Investment in NewStem, Israel-Based Developer of Haploid Stem Cell-Based Diagnostics to Predict Chemotherapy Resistance
- Hollywood Media Advances Pay Date to March 29 for $0.45 per Share Special Distribution
- Hollywood Media Provides Update on Mechanics of Special One-Time Distribution of $0.45 Per Share
Later from NovelStem International
- NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic
- NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy & COVID-19 Resistance; Progress ID'ing Genetic Resistance to Addt'l Anti-Cancer Treatments
- NovelStem Increases NewStem Ownership to 33% as NewStem Preps for 1H'21 FDA Filing for Approval of Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; Initiates Process to Be Publicly Reporting...
- NovelStem Announces NewStem, Ltd. Was Selected by Illumina for its Global Illumina Accelerator
- NovelStem Reviews Efforts to Maximize Value from Legacy Entertainment Asset
Follow NovelStem International into a list and get an email when it puts out news.
Follow NovelStem International